A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/5415 (2006.01) A61K 31/13 (2006.01) A61K 31/454 (2006.01) A61K 31/519 (2006.01) A61K 45/06 (2006.01) A61P 25/00 (2006.01)
Patent
CA 2300148
Nicotine-responsive neuropsychiatric disorders can be treated by administering a nicotine antagonist, particularly mecamylamine. Combination therapy of mecamylamine with a neuroleptic drug also is disclosed. The neuropsychiatric disorders include Tourette's syndrome, schizophrenia, depression, bipolar disorder, tremors, attention deficit hyperactivity disorder, obsessive-compulsive disorder, hemidystonia, rage outbursts and tardive dyskinesia.
On peut traiter des troubles neuropsychiatriques sensibles à la nicotine en administrant un antagoniste de la nicotine, en particulier la mécamylamine. Un traitement associé de mécamylamine avec un médicament neuroleptique est aussi décrit. Les troubles neuropsychiatriques comprennent le syndrome de Tourette, la schizophrénie, la dépression, le trouble bipolaire, les tremblements, l'hyperactivité avec déficit de l'attention, la psychonévrose obsessionnelle, l'hémidystonie, les accès de fureur et les dyskinésies tardives.
Sanberg Paul Ronald
Shytle Roland Douglas
Silver Archie Aaron
Bereskin & Parr Llp/s.e.n.c.r.l.,s.r.l.
University Of South Florida
LandOfFree
Nicotine antagonists for nicotine-responsive... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nicotine antagonists for nicotine-responsive..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nicotine antagonists for nicotine-responsive... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1679108